The selective aldosterone synthase inhibitor Baxdrostat significantly lowers blood pressure in patients with resistant hypertension

Imma Forzano, Pasquale Mone, Fahimeh Varzideh, Stanislovas S. Jankauskas, Urna Kansakar, Antonio De Luca, Gaetano Santulli

Research output: Contribution to journalArticlepeer-review

4 Scopus citations
Original languageEnglish (US)
Article number1097968
JournalFrontiers in Endocrinology
StatePublished - Dec 9 2022


  • BrigHTN
  • CIN-107
  • aldosterone
  • baxdrostat
  • blood pressure
  • clinical trial
  • hypertension
  • resistant hypertension

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this